case_images: PMC11387167_01
case_images: Trough blood level of CsA from January 2020 to May 2022.
case_images: fphar-15-1453034-g001.jpg
case_images: PMC11387167_01_fphar-15-1453034-g001.jpg
case_images: F1
case_images: CsA. CsA was given orally at 5-10 mg per kilogram of body weight per day in two divided doses and then adjusted to a concentration within the appropriate range or an excellent clinical response (Figure 1; Table 1).
case_images: Timeline of alopecia report after exposure to CsA: The case is a 29-month-old boy who developed medication-induced hair loss during cyclosporine therapy for aplastic anemia.
case_images: fphar-15-1453034-g002.jpg
case_images: PMC11387167_01_fphar-15-1453034-g002.jpg
case_images: F2
case_images: In May 2022, he presented with hair loss on the scalp, which spread to the eyebrows and eyelashes (Figure 2).